



Supplementary Figure 3: A) Distribution of ctDNA levels in baseline, on-trial and end-of-treatment samples did not differ between cohort, germline BRCA1/2 status, best response (Kruskal-Wallis tests, $p > 0.01$), patient age at diagnosis or number of cycles completed at end-of-treatment (Spearman's correlation, $p > 0.01$). B) Change in ctDNA levels over time was not associated with cohort, germline BRCA1/2 status, best response (Kruskal-Wallis tests, $p > 0.01$), patient age at diagnosis or number of cycles until end-of-treatment (Spearman's correlation, $p > 0.1$). C) Change in ctDNA levels (increasing or decreasing) was not associated with disease-free survival.